Laura Shawver Buys 30,000 Shares of ARS Pharmaceuticals
Laura Shawver purchased 30,000 shares of ARS Pharmaceuticals on June 24.
Key Points
- Laura Shawver bought 30,000 shares of ARS Pharmaceuticals on June 24, 2026, as part of an insider transaction.
- Shares of ARS Pharmaceuticals traded near $8.54 on Saturday, with a market cap of $848 million.
- Analysts maintain a strong buy consensus, with a mean price target of $28.4 for ARS Pharmaceuticals.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Laura Shawver, a key insider at ARS Pharmaceuticals, Inc., bought 30,000 shares of the company on June 24, 2026. This purchase was part of a series of insider buys that day, reflecting continued confidence in the company's prospects.
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
On June 24, several insiders, including Peter Thompson, Rajeev Dadoo, Brent Saunders, and Saqib Islam, each purchased 30,000 shares of ARS Pharmaceuticals. These transactions were not part of any planned trading program, suggesting a strong belief in the company's future growth.
ARS Pharmaceuticals, Inc. Stock Up 45.0%
Shares of NasdaqGM:SPRY traded near $8.54 on Saturday. ARS Pharmaceuticals has a market cap of approximately $848 million. The company is not currently profitable, with a forward P/E ratio of -10.32. Its beta is 0.826, indicating less volatility compared to the broader market. The stock's 52-week range is between $6.66 and $18.90, with a 50-day moving average of $8.70 and a 200-day moving average of $9.36. The company maintains a high current ratio of 4.94 and a quick ratio of 4.65, though it has a debt-to-equity ratio of 279.24.
$SPRY stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained its "buy" rating for ARS Pharmaceuticals with a price target of $24. Cantor Fitzgerald also maintained a "buy" rating on May 28, 2026, with a $30 target. The consensus among analysts is a "strong buy," with a mean price target of $28.4 based on five opinions.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California. Founded in 2015, it focuses on developing treatments for severe allergic reactions, particularly through its needle-free intranasal delivery of epinephrine, known as neffy. The company operates in the biotechnology sector and is led by CEO Richard E. Lowenthal. ARS Pharmaceuticals employs approximately 154 people and markets its products both in the United States and internationally.
Bottom Line
Laura Shawver's recent purchase is part of a broader pattern of insider buying at ARS Pharmaceuticals, a sign of confidence in the company's pipeline and market position. Investors often watch insider transactions as they can signal management's belief in the company's future. However, it's essential to remember that these filings reflect past actions and may not always predict future performance.
Get ARS Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.